Relationship Between Postoperative Delirium and Heart Function in Valvular Surgery

Valvular Surgery Clinical Trial

Official title:

Relationship Between Postoperative Delirium and Heart Function in Valvular Surgery：A Prospective Observational Cohort Study

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05211934
• Other study ID #: 20220101
• Status: Recruiting
• Start date: January 1, 2022
• Est. completion date: July 1, 2024

Study information

• Verified date: January 2022
• Source: Beijing Anzhen Hospital
• Contact: Jun Ma
• Phone: 13370103571
• Email: majun7689[@]163.com
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Delirium is an acute brain lesion characterized by abnormalities of consciousness, attention, cognition and sensation. Many brain diseases such as stroke, traumatic brain injury and intracranial hypertension can lead to cardiac insufficiency, arrhythmia and heart failure. The incidence of postoperative delirium in patients undergoing cardiac surgery is high. Postoperative delirium is a manifestation of brain function injury. The effect of postoperative delirium on postoperative cardiac function in patients undergoing cardiac surgery is worthy of further discussion.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 300
• Est. completion date: July 1, 2024
• Est. primary completion date: July 1, 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 60 Years to 75 Years

Eligibility

Inclusion Criteria:

• Patients undergoing valvular surgery

• Age between 60 to 75

Exclusion Criteria:

• Have a history of cerebral infarction before operation

• Cardiac function was seriously impaired before surgery

• Neuropsychiatric disorders were present before surgery

Related Conditions & MeSH terms

• Delirium
• Valvular Surgery

Intervention

Other:
• No intervention
No intervention

Locations

Country	Name	City	State
China	Anzhen hospital, Beijing	Beijing	Beijing

Sponsors (1)

Lead Sponsor	Collaborator
Beijing Anzhen Hospital

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	heart function	Doses of norepinephrine, epinephrine, dopamine, dobutamine and vasopressin	up to 60 days